Performance of a cell‐free DNA prenatal screening test, choice of prenatal procedure, and chromosome conditions identified during pregnancy after low‐risk cell‐free DNA screening
- 21 January 2023
- journal article
- research article
- Published by Wiley in Prenatal Diagnosis
- Vol. 43 (2) , 213-225
Abstract
Objectives: To evaluate the performance of cell‐free DNA (cfDNA) screening for common fetal aneuploidies, choice of prenatal procedure, and chromosome conditions identified during pregnancy after low‐risk cfDNA screening.Method: A single‐center prenatal cfDNA screening test was employed to detect trisomies 21, 18, and 13 (T21, T18, T13) and sex chromosome aneuploidies (SCAs). Test performance, choice of prenatal procedure, and cytogenetic results in pregnancies with low‐risk cfDNA screening were reviewed.Results: CfDNA screening of 38,289 consecutive samples identified 720 (1.9%) pregnancies at increased risk for aneuploidy. Positive predictive values (PPVs) for high‐risk singleton pregnancies were 98.5% (T21), 92.5% (T18) and 55.2% (T13). PPVs for SCAs ranged from 30.6% to 95.2%. Most women elected chorionic villus sampling for prenatal diagnosis of T21, T18 and T13; amniocentesis and/or postnatal testing were commonly chosen for SCAs. Cytogenetic tests from 616 screen‐negative pregnancies identified 64 cases (12.7%) with chromosome conditions not detected by cfDNA screening, including triploidy (n = 30) and pathogenic and likely pathogenic copy number variants (n = 34). A further 15 (0.04%) false‐negative common aneuploidy results were identified.Conclusions: CfDNA screening was highly accurate for detecting fetal aneuploidy in this general‐risk obstetric population. Fetal ultrasound and prenatal diagnostic testing were important in identifying chromosome conditions in pregnancies screened as low‐risk.Keywords
This publication has 45 references indexed in Scilit:
- Determination of fetal DNA fraction from the plasma of pregnant women using sequence read countsPrenatal Diagnosis, 2015
- Cell-free DNA Analysis for Noninvasive Examination of TrisomyNew England Journal of Medicine, 2015
- Fetal Sex Chromosome Testing by Maternal Plasma DNA SequencingObstetrics & Gynecology, 2015
- Maternal Source of False-Positive Fetal Sex Chromosome Aneuploidy in Noninvasive Prenatal TestingObstetrics & Gynecology, 2015
- Non‐invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146 958 pregnanciesUltrasound in Obstetrics & Gynecology, 2015
- Fetoplacental mosaicism: potential implications for false-positive and false-negative noninvasive prenatal screening resultsGenetics in Medicine, 2014
- Maternal Mosaicism Is a Significant Contributor to Discordant Sex Chromosomal Aneuploidies Associated with Noninvasive Prenatal TestingClinical Chemistry, 2014
- Circulating Fetal Cell-Free DNA Fractions Differ in Autosomal Aneuploidies and Monosomy XClinical Chemistry, 2014
- Genome-Wide Fetal Aneuploidy Detection by Maternal Plasma DNA SequencingObstetrics & Gynecology, 2012
- American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variantsGenetics in Medicine, 2011